VolitionRX Ltd（VNRX）の株式分析

AI分析 of VolitionRX Ltd (VNRX)

中立

VolitionRX Ltd (VNRX) is currently trading at $0.1936, significantly below its 52-week high of $8.13, indicating potential for upside. However, the company has a troubling year-to-date change of -96.45% and a forward P/E ratio of 20.83, which suggests that while there is growth potential, it is not without risk. The recent partnership with Sysmex for optimizing diagnostic processes highlights a positive catalyst, but the company also reported a net income loss of -$7,326,047 in Q2 2026, which raises concerns about profitability. The RSI is at 52.60, indicating neutral momentum, and the stock is currently a penny stock, which adds to its volatility. The main risk is the high operating expenses that reached $6.3 million in Q1 2026, which could continue to pressure the company's financial health.

アナリスト評価（3）

上値余地 +1062.19%

買い

3 買い

0 中立

0 売り

現在: 0.19

安値

1.50

平均

2.25

高値

3.00

Maxim

買い

$4

2026-06-18

Maxim

2026-06-18

目標株価

$4

買い

D. Boral Capital

中立

—

2026-04-20

D. Boral Capital

2026-04-20

目標株価

—

中立

H.C. Wainwright

買い

$1

2026-04-02

H.C. Wainwright

2026-04-02

目標株価

$1

買い

Maxim

中立

—

2025-12-03

Maxim

2025-12-03

目標株価

—

中立

H.C. Wainwright

買い

—

2025-11-17

H.C. Wainwright

2025-11-17

目標株価

—

買い

すべての評価を見る

バリュエーション指標

VolitionRX Ltd（VNRX）の現在の予想PERは20.83で、5年平均は-0.08です。

予想PER

大幅な割高

5年平均 P/E

-0.08

現在のP/E

20.83

割高

7.85

割安

-8.01

予想EV/EBITDA

適正

5年平均 EV/EBITDA

-1.23

現在のEV/EBITDA

-0.16

割高

0.22

割安

-2.67

予想PSR

適正

5年平均 P/S

47.33

現在のP/S

0.63

割高

136.80

割安

-42.14

Alphio AI による VNRX の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。

強

強気

強気 · 25%VNRX

$0.90

シナリオ価格

基

基本

基本 · 50%VNRX

$0.83

シナリオ価格

弱

弱気

弱気 · 25%VNRX

$0.80

シナリオ価格

VNRX のよくある質問 — Alphio AI が回答

VolitionRx Limited is a company focused on advancing the science of epigenetics. The Company is focused on saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its products are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

VolitionRX Ltd (VNRX) is currently trading at $0.1936, significantly below its 52-week high of $8.13, indicating potential for upside. However, the company has a troubling year-to-date change of -96.45% and a forward P/E ratio of 20.83, which suggests that while there is growth potential, it is not without risk. The recent partnership with Sysmex for optimizing diagnostic processes highlights a positive catalyst, but the company also reported a net income loss of -$7,326,047 in Q2 2026, which raises concerns about profitability. The RSI is at 52.60, indicating neutral momentum, and the stock is currently a penny stock, which adds to its volatility. The main risk is the high operating expenses that reached $6.3 million in Q1 2026, which could continue to pressure the company's financial health.

3 analysts cover VNRX: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 2.25.